Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid QMB control number.

Substitute for form 1449A/PTO Complete if Known INFORMATION DISCLOSURE **Application Number TBA** Filing Date September 8, 2003 STATEMENT BY APPLICANT Mark COOPER First Named Inventor Group Art Unit TBA (use as many sheets as necessary) **Examiner Name** TBA Sheet of 2 003659.00029 Attorney Docket Number

	U.S. PATENT DOCUMENTS					
Examiner Initials *	Cite No.1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant	
		Number - Kind Code ² (# known)			Passages or Relevant Figures Appear	
SL		5,656,611	08/12/1997	Kabanov, et al.		
SL		5,844,107	12/01/1998	Hanson, et al.		
SL		6,177,274	01/23/2001	Park, et al.		
	ļ					
· · ·						

FOREIGN PATENT DOCUMENTS						
Examiner Initials*		Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T⁰
	Cite No. ¹	Country Code ³ - Number ⁴ - Kind Code ⁵ (<i>if known</i>)	Publication Date MM-DD-YYYY			
SL		EP 1031626	08/30/2000	Erbacher, et al.		
SL		WO 97/30731	08/28/1997	Lollo, et al.		
SL		WO 98/46274	10/28/1998	Burgess, et al.		
SL		WO 98/19710	05/14/1998	Schacht, et al.		
·						
			_			
			7			

Examiner Signature	/Scott Long/	Date Considered	07/26/2006

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PTO/SB/08B(10-01)

Approved for use through 10/31/2002. OMB 0851-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO	Complete If Known		
INFORMATION BIGGI COURT	Application Number	TBA	
INFORMATION DISCLOSURE	Filing Date	September 8, 2003	
STATEMENT BY APPLICANT	First Named Inventor	Mark COOPER	
	Group Art Unit	TBA	
(use as many sheets as necessary)	Examiner Name	TBA	
Sheet 2 of 2	Attorney Docket Number	003659.00029	

		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS		
Examiner Initials • Cite No.1		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		
		Aberle, et al., "The counterion influence on cationic lipid-mediated transfection of plasmid DNA", Biochemica et Biophysica Acta, 1996, pages 281-283, Elsevier Science B.V.		
		Allison, et al., "Mechanisms of Protection of Cationic Lipid-DNA Complexes During Lyophilization", Journal of Pharmaceutical Sciences, 2000, pages 682-691, vol. 89, no. 5, Wiley-Liss, Inc., & American Pharmaceutical Association.		
		Choi, et al., "Lactose-Poly (ethylene Glycol)-Grafted Poly-t-Lysine as Hepatoma Cell-Targeted Gene Carrier", Bioconjugate Chem., 1998, pages 708-718, vol. 9, Amerian Chemical Society.		
		Cortesi, et al., "Effecy of DNA Complexion and Freeze-Drying on the Physicochemical Characteristics of Cationic Liposomes", Antisense & Nucleic Drug Development, 2000, pages 205-215, vol. 10, Mary Ann Liebert, Inc.		
		Katayose, et al., "Remarkable Increase in Nuclease Resistance of Plasma DNA through Supramolecular Assembly with Poly (ethylene glycol)-Poly (L-lysine)", Journal of Pharmaceutical Sciences, 1998, vol. 87, no. 2, American Chemical Society and American Pharmaceutical Association.		
		Katayose, et al., "Water-Soluble Polyion Complex Associates of DNA and Poly (ethylene glycol)- Poly (L-lysine) Block Copolymer", Bioconjugate Chem., 1997, pages 702-707, American Chemical Society.		
		Kilcher, et al., "Influence of the DNA Complexation Medium on the Transfection Efficiency of Lipospermine/DNA Particles", Gene Therapy, 1998, pages 855-860, vol. 5, MacMillan Press LTD., Basingstoke, Great Britain.		
		Kwok, et al., "Strategies for Maintaining the Particle Size of Peptide DNA Condensates Following Freeze-Drying", International Journal of Pharmaceutics, 2000, pages 81-88, vol. 203, no. 1-2, Elsevier Science B.V.		
		Li, et al., "Lyophilization of Cationic Lipid-Protamine-DNA (LPD) Complexes", Journal of Pharmaceutical Sciences, 2000, pages 355-364, vol. 89, no. 3, Wiley-Liss, Inc., & American Pharmaceutical Association.		
		Noel, et al., "High Compacted DNA – Polymer Complexes Via New Polynorbornene Polycationic Latexes With Acetate Counterion", SCISEARCH Database, 2000, pages 8980-8983, vol. 16, no. 23, American Chemical Society, Washington, D.C.		
		Pôxon, et al., "The Effect of Lyophilization on Plasmid DNA Activity", Pharmaceutical and Development Technology, 2000, pages 115-122, vol. 5, no. 1, Marcel Dekker, Inc.		
		Toncheva, et al., "Novel vectors for gene delivery formed by self-assembly of NDA with poly (I-lysine) grafted with hydrophilic polymers", Biochemica et Biophysica Acta, 1998, pages 354-368, Elsevier Science B.V.		
		Vinogradov, et al., "Self-Assembly of Polyamine-Poly (ethylene glycol) Copolymers with Phosphorothloate Oligonucleotides", Bioconjugate Chem., 1998, pages 805-812, vol. 9, American Chemical Society.		
		Serres, et al., "DNA Condensation and Transfection of Cells in Culture by a New Polynorbornane Polycationic Polymer, Langmuir 1999, pages 6956-6950, Vol. 15, American Chemical Society		
		Wagner, et al., "Direct Evidence for Counterion Release upon Cationic Lipid- DNA Condensation, Langmuir 2000, pages 303-306, Vol. 16, American Chemical Society		
$\overline{\mathbf{V}}$		Marschall, et al., "Transfer of YACs up to 2.3 Mb intact into human cells with polyethylenimine, Gene Therapy, 1999, pages 1634-1637, Vol. 6		

	المستحدين المستحدين والمستحدد والمستحدد والمستحدد والمستحدد والمستحدد والمستحدد والمستحدد والمستحدد والمستحدد		
Examiner Signature	/Scott Long/	Date Considered	07/26/2006

EXAMINER: Initial if reference considered, whether or not challon is to conformance with MPEP 609. Draw the through claston if not in conformance and not considered, include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be tent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*} Unique citation designation number (optional). * Applicant is to place a check mark here if English language Translation is ettached.